LLY stock holds firm above MA-50 at $950 after Purdue partnership extension: weekly analysis

Traders Union
All News
Financial News
Eli lilly slips 1.58% this week

Highlights

Eli Lilly’s price remains in a robust uptrend, currently trading significantly above key long-term support levels.
Momentum indicators confirm continued upside strength, but overbought conditions signal the potential for near-term buyer fatigue.
The expected seven-day price range is $1,160–$1,245, with a 75% probability of further gains and consolidation likely unless support at $1,160 fails.

Innovation spending and regulatory wins underpin positive sentiment this week

Eli Lilly announced a $250 million commitment to pharmaceutical innovation and workforce development through a partnership extension with Purdue University, reinforcing its investment in US research and manufacturing. Regulatory progress also supported sentiment, as the European Medicines Agency approved Jaypirca and Medicare launched a $50/month GLP-1 Bridge program for Zepbound. The company shared updates on two Phase 3 studies for its Alzheimer's therapy, donanemab, while also debuting Foundayo, a new oral GLP-1 drug in the obesity market.

Momentum remains strong as overbought signals raise caution over the week

On the weekly chart, LLY trades well above key moving averages — MA-20 ($1,019.41), MA-50 ($950.14), and MA-200 ($714.77) — affirming the prevailing uptrend. Strong bullish momentum persists as shown by MACD and ADX readings, although oscillators such as RSI (69.67), Stochastic RSI (100.00), CCI (168.28), and Bull/Bear Power (149.04) are deep in overbought territory. MA-50 at $950.14 and the Ichimoku Kijun, more than 30% below the current price, highlight significant dynamic support, while the Awesome Oscillator remains positive, supporting further upside despite signals of possible buyer exhaustion.

Sideways bias with upside breakout risk as overbought signals emerge

For the next five trading days, LLY is expected to consolidate between $1,160 and $1,245, with the overall trend favoring continued sideways movement. There is roughly a 75% chance of additional price gains given that 3 out of 4 key weekly indicators remain in Buy or Strong Buy territory, but oscillators warn of potential normalization if overbought conditions trigger profit-taking. A breakout above $1,245 would confirm bullish continuation and potentially open further highs, while a drop below $1,160 could accelerate a pullback toward lower support levels on the weekly timeframe.

Previously it was reported that Medicare's temporary Bridge program expanded access to GLP-1 obesity drugs for eligible seniors, highlighting both new opportunities and lingering policy uncertainties for manufacturers such as Eli Lilly. With fresh regulatory approvals, major R&D investments, and the promising launch of new therapies, Eli Lilly’s multi-pronged momentum strengthens the bullish narrative, but traders should monitor for potential volatility if overbought technical conditions trigger a shift from consolidation to corrective action.

Source of Data: LLY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.